# A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

> **NCT03703908** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 5 (actual)

## Conditions studied

- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** CCX140-B

## Key facts

- **NCT ID:** NCT03703908
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-01
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-06-24
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Program not advancing
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703908, "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03703908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*